zoom_in Click to enlarge

James Allison

▲ ▼

description James Allison Overview

James Allison is an American immunologist recognized for his groundbreaking work on T cell receptors. His research fundamentally shifted cancer treatment strategies by demonstrating how to activate the body’s immune system to specifically target and destroy tumors. This approach has become a cornerstone of modern immunotherapy. Allison received the 2018 Nobel Prize in Physiology or Medicine for this impactful contribution to cancer research, benefiting patients with various cancers and advancing immunological understanding.

help James Allison FAQ

What cancer drug was developed from James Allison's research?

Allison's research on the CTLA-4 immune checkpoint protein led to the development of ipilimumab, marketed as Yervoy by Bristol-Myers Squibb. The FDA approved ipilimumab in 2011 for metastatic melanoma, making it the first immune checkpoint inhibitor ever approved for cancer treatment.

How does CTLA-4 blocking actually fight tumors?

CTLA-4 is a receptor on T cells that acts as a natural brake on immune responses, preventing T cells from over-activating. Allison discovered that blocking CTLA-4 with an antibody releases this brake, allowing T cells to mount a sustained attack against cancer cells that they previously ignored.

When did James Allison win the Nobel Prize for cancer immunotherapy?

Allison received the 2018 Nobel Prize in Physiology or Medicine, shared with Tasuku Honjo of Kyoto University, who discovered the PD-1 checkpoint protein. The Nobel Committee cited their work as establishing an entirely new principle in cancer therapy.

Where does James Allison currently conduct his research?

Allison has been based at the University of Texas MD Anderson Cancer Center since 2012, where he chairs the Department of Immunology. Prior to MD Anderson, he conducted research at UC Berkeley and Memorial Sloan Kettering Cancer Center.